Company Advances Latest Knowledge Across a Broad Range of Topics,
With Clinical Relevance for Eye Care Professionals Worldwide
SAN RAMON, CALIF., March 7, 2024—The 2024 Netherlands Contact Lens Congress (NCC) theme is “Future Generation,” complementing CooperVision’s dynamic scientific program at the event. CooperVision and its research partners will present multiple papers that seek to advance the eye care category, with high clinical relevance for eye care professionals (ECPs) worldwide. NCC takes place in Veldhoven, the Netherlands from March 10-11, in collaboration with the British Contact Lens Association (BCLA) for the scientific symposium.
“Our science at NCC addresses several topics that are of substantial interest to ECPs, including better understanding new patients’ contact lens journeys to reduce dropout, prescribing trends related to the myopia epidemic, and methods to evaluate the vision performance of myopia control contact lenses,” said Francis Erard, CooperVision’s Vice President of Research and Development. “They’re part of CooperVision’s commitment to using an evidence-based approach to constantly improve eye health in partnership with the eye care community.”
New CooperVision-led research has uncovered insights that may help prevent neophyte contact lens wearers from dropping out of the category. “Understanding the Initial Contact Lens Journey and Consequences of a Protracted Experience” (Watson S, et al.) used a quantitative survey (n=500) and qualitative interviews (n=12) with both new contact lens wearers (≤12 months) and potential wearers (50:50 ratio) to discover patient expectations and emotions.
Findings indicated multiple opportunities for improvement to current procedures. For example, the vast majority (84%) of patients didn’t feel confident on the day of their first contact lens appointment, but less than half (45%) had been given information about what to expect from the practice. Protracted patient journeys due to contact lenses not being available for same day take home, a lack of consolidated practice visits, and staff limitations surrounding application and removal training were also problematic. Two-thirds (67%) of potential wearers would buy online, discontinue the process, or go elsewhere if it was necessary to return to the practice several times.
CooperVision will also present papers during NCC regarding utilization of myopia control interventions compared to myopia prevalence, performance of its DreamLite® orthokeratology lenses, data from its groundbreaking multi-year MiSight® 1 day clinical trial, contact lens handling characteristics, myopia control contact lens performance measures, and scleral lens wear amongst patients with dryness symptoms. The company will also exhibit at NCC, demonstrating its portfolio of inventive products such as MyDay® daily disposable lenses and clariti® 1 day lenses that improve lives, one person at a time.
Held biennially, NCC is attended by eye care professionals, educators, researchers, and manufacturers from the Netherlands, Europe, and around the globe. For more information on the 2024 event’s sessions and speakers, visit contactlenscongress.com.
###
About CooperVision
CooperVision, a division of CooperCompanies (Nasdaq:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com
About CooperCompanies
CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates through two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, improving the vision of millions of people every day. CooperSurgical is a leading fertility and women’s health company dedicated to assisting women, babies and families at the healthcare moments that matter most. Headquartered in San Ramon, Calif., CooperCompanies has a workforce of more than 15,000 with products sold in over 130 countries. For more information, please visit www.coopercos.com
Media Contact
Mike McDougall, APR, Fellow PRSA, FAAO
McDougall Communications for CooperVision
mike@mcdougallpr.com or +1.585.545.1815